Paramagnetic oil emulsions as oral magnetic resonance imaging contrast agents

Dynamic High-Field MR Imaging in Experimental Porcine Acute Pancreatitis

The effects of acute pancreatitis on MR imaging signal intensities (SIs) were determined in an experimental study at 1.0 T. Oedematous pancreatitis was induced in 9 piglets and haemorrhagic pancreatitis in 11 piglets. Each animal served as its own control for MR imaging before and after induction of pancreatitis. T1-weighted spin echo (450/15 ms) and dynamic turbo FLASH (flip angle 8°) sequences were used without contrast medium in testing the stability of the SI measurements. There was no significant difference in the SI-versus-time curves of the pancreas in piglets with oedematous and haemorrhagic pancreatitis. However, the difference in mean SIs between healthy and diseased piglets was significant. Thus, although non-contrast MR may be useful in the diagnosis of acute pancreatitis, it does not distinguish between oedematous and haemorrhagic pancreatitis.

Small bowel

MR imaging, using modern equipment and a rigorous technical approach, can offer detailed morphologic information and functional data on the small bowel. The optimal study technique is debatable, although the oral administration of contrast material as a first-line approach is less expensive, faster, easier to perform, and better tolerated by patients. MR enteroclysis might be reserved for selected cases as a second-line study. The major clinical indication is the evaluation of patients who have suspected or known Crohn's disease. The absence of ionizing radiation, considering the young age of most of the patients and the frequency of the examinations, is an important advantage over other techniques (radiograph and CT enteroclysis).

Oral contrast agents for magnetic resonance imaging of the bowel

The development of fast imaging sequences, which provide the ability to acquire motion-free T1- and T2-weighted images of static fluids, has greatly increased the interest in magnetic resonance imaging of the small bowel. Luminal distension is a necessary prerequisite for small bowel imaging methods because collapsed bowel loops can hide even large lesions and may mimic wall thickening. Poor distension of normal bowel loops in basal conditions has led researchers to study different oral contrast media to optimally distend the bowel lumen. Several MR oral contrast agents with various signal properties are available. According to these signal properties, agents are classified as positive ("bright" lumen), negative ("dark" lumen), or biphasic ("bright" lumen on T1 and "dark" on T2, or conversely "dark" lumen on T2 and "bright" on T1). Positive contrast agents cause a reduction in T1 relaxation time; consequently, these agents act on T1-weighted images by increasing the signal intensity of the bowel lumen. Negative contrast agents are based on superparamagnetic particles and act by inducing local field inhomogeneities, which results in shortening of both T1 and T2 relaxation times. Using superparamagnetic contrast agents, T2-weighted effects are predominant. Biphasic contrast agents are substances that have different signal intensities on different sequences, depending on the concentration at which they are administered. The choice of a single agent presents advantages and disadvantages; thus, the radiologist should choose the appropriate contrast medium according to the clinical setting, MR experience, availability of the agent, and patient tolerance.

Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population

OBJECTIVE

To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population.

MATERIALS AND METHODS

A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs.

RESULTS

With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85 % of the subjects on T1-weighted images and for 95 % of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92 % of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71 % to 100 %. For at least 75 % of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron.

CONCLUSION

Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.

MR cholangiopancreatography before and after oral blueberry juice administration

Blueberry juice was used in 37 patients who underwent MR cholangiopancreatography (MRCP) examination. Quantitative and qualitative comparison between pre- and post-blueberry juice oral administration was made. Common bile duct and main pancreatic duct depiction improved statistically significantly (p < 0.05) after blueberry juice administration. Blueberry juice may be used routinely in MRCP studies as a natural, safe, and inexpensive negative contrast agent with high efficacy.

Simultaneous in vivo visualization and localization of solid oral dosage forms in the rat gastrointestinal tract by magnetic resonance imaging (MRI)

PURPOSE

Bioavailability of orally administered drugs is much influenced by the behavior, performance and fate of the dosage form within the gastrointestinal (GI) tract. Therefore, MRI in vivo methods that allow for the simultaneous visualization of solid oral dosage forms and anatomical structures of the GI tract have been investigated.

METHODS

Oral contrast agents containing Gd-DTPA were used to depict the lumen of the digestive organs. Solid oral dosage forms were visualized in a rat model by a 1H-MRI double contrast technique (magnetite-labelled microtablets) and a combination of 1H- and 19F-MRI (fluorine-labelled minicapsules).

RESULTS

Simultaneous visualization of solid oral dosage forms and the GI environment in the rat was possible using MRI. Microtablets could reproducibly be monitored in the rat stomach and in the intestines using a 1H-MRI double contrast technique. Fluorine-labelled minicapsules were detectable in the rat stomach by a combination of 1H- and 19F-MRI in vivo.

CONCLUSIONS

The in vivo 1H-MRI double contrast technique described allows solid oral dosage forms in the rat GI tract to be depicted. Solid dosage forms can easily be labelled by incorporating trace amounts of non-toxic iron oxide (magnetite) particles. 1H-MRI is a promising tool for observing such pharmaceutical dosage forms in humans. Combined 1H- and 19F-MRI offer a means of unambiguously localizing solid oral dosage forms in more distal parts of the GI tract. Studies correlating MRI examinations with drug plasma levels could provide valuable information for the development of pharmaceutical dosage forms.

Invited review: biophysical properties and clinical applications of magnetic resonance imaging contrast agents

Contrast enhanced magnetic resonance imaging (MRI) is a very versatile and effective technique for detecting and characterizing lesions, for identifying a variety of patho-physiological abnormalities, and for providing perfusion and functional information. The application of contrast enhanced MRI to many clinical and research indications has emerged because of the rapid evolution in imaging techniques, improved methodology, and the development of efficient and specific contrast agents. Problems related to optimizing parameters and dosage have been due to complex interplay of relaxation times, biophysical mechanisms and acquisition parameters. A knowledge of basic biophysical aspects is therefore essential for a full understanding of the results obtained for different organs under different conditions, and for optimizing the image parameters and dosage of contrast agents. This article underlines the biophysical basis of the effects of contrast agents in MRI, identifies the problems involved in optimizing the parameters for maximum efficiency, and presents a general overview of the clinical studies and research applications in the central nervous system, perfusion abnormalities, hepatobiliary system, musculoskeletal system and the gastrointestinal tract. The section on perfusion studies includes a discussion of quantitative analysis and kinetic models describing the effects of contrast agents. Finally, a critical evaluation of the scope and limitations of contrast enhanced MRI is presented.

MR imaging of Crohn disease: use of perflubron as a gastrointestinal contrast agent

This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post-perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.

Large scale clinical evaluation of bowel contrast agent containing ferric ammonium citrate in MRI

Clear identification of bowel has been thought to be essential in diagnosis by abdominal MRI. We have completed the clinical phase III trial of a new oral contrast agent (FerriSeltz) which is a ferric ammonium citrate based bowel contrast agent. FerriSeltz is a powder that is dissolved in 300 ml water to create a grape-flavored effervescent drink. We have evaluated the usefulness of FerriSeltz, and compared groups receiving 600 mg and 1200 mg of ferric ammonium citrate, the use and nonuse of parasympathetic blockers, and patients with and without fasting in 174 patients who underwent abdominal MRI using this agent. FerriSeltz was found to brighten the stomach and duodenum, contribute to the improvement in diagnostic efficacy, be safe as a bowel contrast agent in abdominal MRI, and be associated with an extremely low incidence of side effects (only mild diarrhea in one of 169 patients). No significant differences were found in the contribution to the improvement in diagnostic efficacy between the two dosage groups, the use and nonuse of parasympathetic blockers, or patients with and without fasting. We concluded that ferric ammonium citrate based compound (FerriSeltz) is a promising bowel contrast agent in abdominal MRI.

Magnetic resonance imaging of lower abdominal and pelvic lesions: assessment of oral magnetic particles as an intestinal contrast agent

To determine the value of oral magnetic particles (OMP) as a superparamagnetic MR contrast agent for the gastrointestinal tract in lower abdominal and pelvic lesions, 30 patients underwent spin-echo imaging before and after ingestion of OMP at a dose of approximately 80 mg of iron in 800 ml water. The preparation was divided into four portions and taken by the patient over a 2-h period. Two readers independently reviewed the MR images. The contrast material was well tolerated and the distribution of the contrast material was good to excellent in the proximal and pelvic small bowel, but was not sufficient in the colon with the dose and timing used in the study. Postcontrast images showed a significantly better delineation of the lesions, the small bowel, and the paraaortic region, but no significant improvement in the delineation of the colon, the iliac vessels area, the bladder or genital tract. Compared with precontrast images, confidence in defining or excluding disease on postcontrast images was better, equal or worse in 40, 60 and 0% of cases, respectively (P less than 0.001) with a substantial agreement between readers (kappa = 0.71). OMP produced susceptibility artefacts of significant intensity in only one case. These results indicate that OMP may be useful in the delineation of lower abdominal and pelvic lesions at MR imaging. Marking of the colon by a contrast agent might improve the results.

OMR, a positive bowel contrast agent for abdominal and pelvic MR imaging: safety and imaging characteristics

To determine the safety and imaging characteristics of OMR--an effervescent solution of ferric ammonium citrate--as a bowel contrast agent, magnetic resonance (MR) imaging at 1.5 T was performed in 29 volunteers. T1- and T2-weighted images of the upper abdomen and pelvis were obtained before and after oral administration of OMR at doses of 100-400 mg of iron in 300-600 mL of water. Respiratory-ordered phase encoding and presaturation pulses were used routinely for artifact suppression. All dose levels of OMR provided marking of the bowel by increasing intraluminal signal intensity; however, the degree and percentage of small bowel opacification appeared more prominent at higher dose levels of iron. Semisolid or watery bowel movements were noted in 31% of subjects, but no clinically important laboratory abnormalities were seen. OMR improved delineation of the head of the pancreas on T1-weighted images in 72% of subjects but was less useful in defining the body and tail. OMR is a safe and effective bowel contrast agent for MR imaging. Because artifacts due to movement of hyperintense bowel may degrade the images, OMR may be most useful on short TR/TE or fast imaging pulse sequences or when combined with antiperistaltic agents.